WO2001019321A3 - Methods for treating neuropathic pain using hetreoarylmethanesulfonamides - Google Patents

Methods for treating neuropathic pain using hetreoarylmethanesulfonamides Download PDF

Info

Publication number
WO2001019321A3
WO2001019321A3 PCT/US2000/025342 US0025342W WO0119321A3 WO 2001019321 A3 WO2001019321 A3 WO 2001019321A3 US 0025342 W US0025342 W US 0025342W WO 0119321 A3 WO0119321 A3 WO 0119321A3
Authority
WO
WIPO (PCT)
Prior art keywords
hetreoarylmethanesulfonamides
methods
neuropathic pain
treating neuropathic
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/025342
Other languages
French (fr)
Other versions
WO2001019321A2 (en
Inventor
Mark J Benedyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Priority to EP00965045A priority Critical patent/EP1215963A4/en
Priority to JP2001522959A priority patent/JP2003509349A/en
Publication of WO2001019321A2 publication Critical patent/WO2001019321A2/en
Publication of WO2001019321A3 publication Critical patent/WO2001019321A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A method of treating neurophatic pain and its progression is disclosed. The method includes administering to a subject a compound of formula (I) wherein R is hydrogen or a halogen atom, R2 and R3 are the same or different and are each hydrogen or a straight or branched alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the methanesulfonamide group is bonded to the carbon atom of either X and Y, a specific example of such example of such a compound is exemplified by zonisamide.
PCT/US2000/025342 1999-09-15 2000-09-15 Methods for treating neuropathic pain using hetreoarylmethanesulfonamides Ceased WO2001019321A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00965045A EP1215963A4 (en) 1999-09-15 2000-09-15 Methods for treating neuropathic pain using hetreoarylmethanesulfonamides
JP2001522959A JP2003509349A (en) 1999-09-15 2000-09-15 A method for treating neuropathic pain using a heteroarylmethanesulfonamide.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15393999P 1999-09-15 1999-09-15
US60/153,939 1999-09-15

Publications (2)

Publication Number Publication Date
WO2001019321A2 WO2001019321A2 (en) 2001-03-22
WO2001019321A3 true WO2001019321A3 (en) 2001-10-04

Family

ID=22549338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025342 Ceased WO2001019321A2 (en) 1999-09-15 2000-09-15 Methods for treating neuropathic pain using hetreoarylmethanesulfonamides

Country Status (4)

Country Link
US (1) US6489350B1 (en)
EP (1) EP1215963A4 (en)
JP (1) JP2003509349A (en)
WO (1) WO2001019321A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030036556A1 (en) * 2001-06-29 2003-02-20 Jennings Julianne E. Zonisamide use in headache
WO2003007953A1 (en) * 2001-07-18 2003-01-30 Washington University Methods and compositions for modulating t-type calcium channels
US20050059718A1 (en) * 2003-02-21 2005-03-17 Hayato Miyachi Methods of using zonisamide as an adjunctive therapy for partial seizures
JP2004331653A (en) * 2003-04-14 2004-11-25 Mitsubishi Pharma Corp Agent for preventing and / or treating pain
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20050043773A1 (en) * 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043705A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050043704A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154032A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154033A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154037A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154035A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154036A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
SE0400378D0 (en) * 2004-02-17 2004-02-17 Jan Hedner Methods to treat and diagnose respiratory disorders in sleep and agents to perform the procedure
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
PL1954241T3 (en) * 2005-11-28 2013-03-29 Orexigen Therapeutics Inc Sustained-release formulation of zonisamide
ES2690205T3 (en) * 2006-04-13 2018-11-19 Neurotech Pharmaceuticals Co., Ltd. Pharmaceutical composition to treat or prevent inflammatory diseases
US7585875B2 (en) * 2006-06-06 2009-09-08 Avigen, Inc. Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN102724878A (en) 2010-01-11 2012-10-10 奥雷西根治疗公司 Approach to providing weight loss therapy in patients with major depressive disorder
HUE072188T2 (en) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Preparation for use in a procedure for the treatment of overweight and obese patients at high cardiovascular risk
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
KR102279993B1 (en) 2015-09-23 2021-07-21 엑스더블유파마 리미티드 Precursors of gamma-hydroxybutyric acid and compositions and uses thereof
CN109310640A (en) 2016-06-09 2019-02-05 Ds 制药动物健康株式会社 Sustained-release formulation composition for animals
BR112019020464A2 (en) 2017-03-30 2020-04-28 Xw Laboratories Inc. compounds derived from bicyclic heteroaryl, pharmaceutical composition comprising said compounds, transdermal patch comprising said composition and therapeutic use of the compounds and composition
EP3856719B1 (en) 2018-09-30 2023-06-07 XWPharma Ltd. Compounds as neuronal histamine receptor-3 antagonists and uses thereof
TW202547822A (en) 2019-12-20 2025-12-16 香港商凱瑞康寧有限公司 Methods of synthesizing 4-valyloxybutyric acid
EP4167971A1 (en) 2020-06-18 2023-04-26 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
EP4167966A1 (en) 2020-06-18 2023-04-26 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
TW202214580A (en) * 2020-07-07 2022-04-16 日商大日本住友製藥股份有限公司 Benzisoxazole derivative
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
CN119970650A (en) 2020-10-05 2025-05-13 凯瑞康宁生物工程有限公司 Modified release compositions of gamma-hydroxybutyric acid derivatives
EP4308086B1 (en) 2021-03-19 2025-10-15 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396748B1 (en) * 1987-12-29 1993-10-13 Dainippon Pharmaceutical Co., Ltd. Agent for treating ischemic brain trouble

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1215963A4 *

Also Published As

Publication number Publication date
JP2003509349A (en) 2003-03-11
US6489350B1 (en) 2002-12-03
WO2001019321A2 (en) 2001-03-22
EP1215963A2 (en) 2002-06-26
EP1215963A4 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
EP0842661A3 (en) Atherosclerosis treatment
CA2328780A1 (en) Dihydropyrimidines
IL144170A0 (en) 4-oxo-1,4-dihydro-3-quinolinecarboamides as antiviral agents
IE890906L (en) Method of lowering the blood pressure
AU5242000A (en) Nematicidal trifluorobutenes
EP0945452A4 (en) Sugar compounds, gelling agents, gelling agent compositions, processes for the preparation of them, and gel compositions
AU3744397A (en) Total synthesis of antitumor acylfulvenes
EP0879841A3 (en) Silicon compound, method for making the same, and electroluminescent device using the same
PT1447400E (en) Bicyclic compound
BG104569A (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds
EP0194599A3 (en) Benzamide derivatives, process for producing the same, and soil fungicides containing the same
CA2323150A1 (en) New porphyrins and their use
NO882626D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES.
CA2309474A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
CA2191947A1 (en) Pirydyl Imidazole Derivatives and Processes for the Preparation Thereof
TR200001819T2 (en) COPD treatment method.
EP0900785A3 (en) Vitamin A related compounds and process for producing the same
EP1072595A3 (en) 4-arylpiperidine derivatives for the treatment of pruritus
EP1101767A3 (en) Oligosiloxane and method of preparing same
BG103398A (en) New derivatives of erythromicyn, method for their preparation and application as medicmentous forms
WO2002002098A3 (en) Antibacterial method and composition with phenolic compounds
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders
SE9802546D0 (en) Medicinal product and method for treatment and prevention of dyskinesia
EP1083247A3 (en) Use of organic carbonates as solvents for the washing of metal surfaces
MX9702089A (en) Bicyclic carboxamides as 5-ht1a antagonists.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 522959

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000965045

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000965045

Country of ref document: EP